X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (160) 160
humans (158) 158
abacavir-lamivudine (155) 155
infectious diseases (151) 151
hiv infections - drug therapy (129) 129
male (113) 113
female (109) 109
hiv (104) 104
adult (101) 101
antiretroviral therapy (93) 93
tenofovir (90) 90
immunology (86) 86
middle aged (84) 84
anti-hiv agents - therapeutic use (76) 76
emtricitabine (74) 74
anti-hiv agents - adverse effects (60) 60
hiv-infected patients (50) 50
abacavir/lamivudine (49) 49
aids/hiv (48) 48
hiv infection (48) 48
tenofovir disoproxil fumarate (48) 48
virology (48) 48
efavirenz (46) 46
pharmacology & pharmacy (45) 45
osteoporosis (44) 44
hiv infections - complications (43) 43
bone mineral density (42) 42
bone density - drug effects (40) 40
treatment outcome (40) 40
bone density (39) 39
mineral density (39) 39
bone-mineral density (37) 37
adenine - analogs & derivatives (36) 36
human immunodeficiency virus--hiv (36) 36
microbiology (35) 35
density (34) 34
hiv infections - virology (34) 34
bones (32) 32
abacavir (31) 31
prevalence (31) 31
viral load (31) 31
anti-hiv agents - administration & dosage (30) 30
protease inhibitors (30) 30
lamivudine (29) 29
therapy (29) 29
antiviral agents (27) 27
double-blind (27) 27
drug therapy, combination (27) 27
hiv-1 (27) 27
hiv-1-infected patients (27) 27
efficacy (26) 26
health aspects (26) 26
young adult (26) 26
antiretroviral drugs (25) 25
cd4 lymphocyte count (25) 25
drug therapy (25) 25
absorptiometry, photon (24) 24
adolescent (24) 24
adults (24) 24
disoproxil fumarate (24) 24
drug combinations (24) 24
infected patients (24) 24
tenofovir - therapeutic use (24) 24
tenofovir/emtricitabine (24) 24
safety (23) 23
highly active antiretroviral therapy (22) 22
lamivudine - therapeutic use (22) 22
risk factors (22) 22
aged (21) 21
article (21) 21
initial treatment (21) 21
adenine - therapeutic use (20) 20
dideoxynucleosides - therapeutic use (20) 20
fracture risk (20) 20
adenine - adverse effects (19) 19
aids (19) 19
bone (19) 19
care and treatment (19) 19
fracture (19) 19
analysis (18) 18
deoxycytidine - analogs & derivatives (18) 18
fractures (18) 18
hiv-1 - drug effects (18) 18
human immunodeficiency virus (18) 18
human-immunodeficiency-virus (18) 18
men (18) 18
tenofovir - adverse effects (18) 18
active antiretroviral therapy (17) 17
antiretroviral agents (17) 17
antiretroviral therapy, highly active - methods (17) 17
antiretroviral-naive (17) 17
clinical trials (17) 17
naive patients (17) 17
organophosphonates - adverse effects (17) 17
prospective studies (17) 17
raltegravir (17) 17
ritonavir - therapeutic use (17) 17
cross-sectional studies (16) 16
virus diseases (16) 16
acquired immune deficiency syndrome--aids (15) 15
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal Article
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, ISSN 1525-4135, 06/2017, Volume 75, Issue 2, pp. 226 - 231
In a double-blind, phase 3 trial, 663 HIV-infected, virologically suppressed adults were randomized to switch to tenofovir alafenamide (TAF; n = 333) vs.... 
osteopenia | ANTIRETROVIRAL-NAIVE | INFECTIOUS DISEASES | ABACAVIR-LAMIVUDINE | ELVITEGRAVIR | proteinuria | COBICISTAT | EMTRICITABINE | IMMUNOLOGY | DENSITY | HIV | EFAVIRENZ | DOUBLE-BLIND | ABACAVIR/LAMIVUDINE | tenofovir alafenamide | TENOFOVIR/EMTRICITABINE
Journal Article
Lancet Infectious Diseases, The, ISSN 1473-3099, 2016, Volume 16, Issue 1, pp. 43 - 52
Journal Article
Lancet, The, ISSN 0140-6736, 2015, Volume 385, Issue 9987, pp. 2606 - 2615
Summary Background Tenofovir disoproxil fumarate can cause renal and bone toxic effects related to high plasma tenofovir concentrations. Tenofovir alafenamide... 
Internal Medicine | KIDNEY-DISEASE | RATES | MEDICINE, GENERAL & INTERNAL | ABACAVIR-LAMIVUDINE | BONE-MINERAL DENSITY | SAFETY | ADULTS | ANTIRETROVIRAL THERAPY | LOPINAVIR/RITONAVIR | COUNT | EXPOSURE | Humans | Male | Thiazoles - administration & dosage | Carbamates - administration & dosage | Arthralgia - chemically induced | Thiazoles - adverse effects | Sleep Initiation and Maintenance Disorders - chemically induced | Tenofovir | Adenine - adverse effects | Quinolones - adverse effects | Adult | Anti-HIV Agents - therapeutic use | Deoxycytidine - adverse effects | Female | Headache - chemically induced | Emtricitabine | Adenine - analogs & derivatives | Kidney - drug effects | Respiration Disorders - chemically induced | Double-Blind Method | Anti-HIV Agents - adverse effects | Deoxycytidine - administration & dosage | HIV Infections - virology | Organophosphonates - adverse effects | Treatment Outcome | CD4 Lymphocyte Count | Nausea | Adenine - administration & dosage | Organophosphonates - administration & dosage | Bone Density - drug effects | Quinolones - administration & dosage | Carbamates - adverse effects | HIV Infections - drug therapy | Viral Load - drug effects | Cobicistat | Deoxycytidine - analogs & derivatives | Drug Combinations | Medical colleges | Clinical trials | Cross infection | Nosocomial infections | HIV (Viruses) | Drug therapy | Health aspects | HIV infection | Analysis | Antiretroviral drugs | Infections | Acquired immune deficiency syndrome--AIDS | Human immunodeficiency virus--HIV
Journal Article
Enfermedades Infecciosas y Microbiologia Clinica, ISSN 0213-005X, 01/2018, Volume 36, Issue 1, pp. 29 - 33
Objective To describe the experience using the combination abacavir, lamivudine plus non-boosted atazanavir (ABC/3TC+ATV) in a group of pretreated patients.... 
Atazanavir in routine clinical practice | Unboosted atazanavir | Abacavir/lamivudine + atazanavir
Journal Article
Antimicrobial Agents and Chemotherapy, ISSN 0066-4804, 04/2019, Volume 63, Issue 4
AIDS Clinical Trial Group study A5202 (ClinicalTrials.gov identifier NCT00118898) was a phase 3b, randomized, partially blinded equivalence study of open-label... 
Tenofovir | Pharmacokinetics | Population pharmacokinetics | ABACAVIR-LAMIVUDINE | IMPACT | tenofovir | PART | EMTRICITABINE | EFAVIRENZ | pharmacokinetics | INITIAL TREATMENT | MICROBIOLOGY | PHARMACOLOGY & PHARMACY | population pharmacokinetics | RITONAVIR | Index Medicus
Journal Article
Clinical Infectious Diseases, ISSN 1058-4838, 08/2015, Volume 61, Issue 4, pp. 572 - 580
Journal Article
JAIDS Journal of Acquired Immune Deficiency Syndromes, ISSN 1525-4135, 08/2015, Volume 69, Issue 4, pp. 439 - 445
Journal Article
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, ISSN 1525-4135, 11/2016, Volume 73, Issue 3, pp. 294 - 298
Coformulated elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide (E/C/F/TAF) has high efficacy and improved renal and bone safety in multiple... 
ANTIRETROVIRAL-NAIVE | INFECTIOUS DISEASES | ABACAVIR-LAMIVUDINE | elvitegravir | CHRONIC HEPATITIS-B | EMTRICITABINE | bone | IMMUNOLOGY | HIV-INFECTED PATIENTS | renal | DENSITY | TENOFOVIR DISOPROXIL FUMARATE | HIV | PHARMACOKINETICS | EFAVIRENZ | TAF | tenofovir alafenamide | HBV | coinfection
Journal Article
AIDS, ISSN 0269-9370, 11/2015, Volume 29, Issue 18, pp. 2459 - 2464
Objective:Antiretroviral therapy initiation has been linked to bone mineral density and bone biomarker changes. We assessed long-term bone turnover biomarker... 
POPULATION | INFECTIOUS DISEASES | ABACAVIR-LAMIVUDINE | RALTEGRAVIR | tenofovir | EMTRICITABINE | dolutegravir | IMMUNOLOGY | OSTEOPOROSIS | HIV-INFECTED PATIENTS | MINERAL DENSITY | VIROLOGY | bone markers | osteocalcin | FRACTURES | abacavir | TENOFOVIR/EMTRICITABINE | efavirenz
Journal Article
Lancet Infectious Diseases, The, ISSN 1473-3099, 2015, Volume 15, Issue 7, pp. 775 - 784
Summary Background Problems associated with lifelong antiretroviral therapy, such as need for strict adherence, drug-related toxic effects, difficulties with... 
Infectious Disease | INFECTIOUS DISEASES | ABACAVIR-LAMIVUDINE | EFFICACY | SAFETY | NAIVE HIV-1-INFECTED PATIENTS | ACTIVE ANTIRETROVIRAL THERAPY | ONCE-DAILY ATAZANAVIR/RITONAVIR | TWICE-DAILY LOPINAVIR/RITONAVIR | INFECTED PATIENTS | PROTEASE INHIBITORS | TENOFOVIR | HIV-1 | Humans | Middle Aged | Male | RNA, Viral - blood | Viral Load | Oligopeptides - therapeutic use | Reverse Transcriptase Inhibitors - adverse effects | Tenofovir | Deoxycytidine - therapeutic use | Drug Therapy, Combination - adverse effects | Adenine - therapeutic use | Lamivudine - therapeutic use | Atazanavir Sulfate | Ritonavir - therapeutic use | Adult | Anti-HIV Agents - therapeutic use | Female | Reverse Transcriptase Inhibitors - therapeutic use | Pyridines - therapeutic use | Emtricitabine | HIV Protease Inhibitors - adverse effects | Adenine - analogs & derivatives | Organophosphonates - therapeutic use | Anti-HIV Agents - adverse effects | HIV Infections - virology | HIV Protease Inhibitors - therapeutic use | Drug Therapy, Combination - methods | HIV Infections - drug therapy | Zidovudine - therapeutic use | Drug Substitution | Deoxycytidine - analogs & derivatives | Studies | Antiretroviral drugs | Heart attacks | Protease inhibitors | Acquired immune deficiency syndrome--AIDS | Human immunodeficiency virus--HIV | Clinical trials | Infections | Mutation | Drug therapy | Failure | Cost control | Index Medicus
Journal Article
PLOS ONE, ISSN 1932-6203, 05/2014, Volume 9, Issue 5
Objective: Simplification of antiretroviral therapy in patients with suppressed viremia may minimize long-term adverse effects. The study's primary objective... 
UNBOOSTED ATAZANAVIR | PROTEASE INHIBITOR | ABACAVIR-LAMIVUDINE | MINERAL DENSITY | EFFICACY | MULTIDISCIPLINARY SCIENCES | POSITIVE PATIENTS | ANTIRETROVIRAL THERAPY | HIV-1-INFECTED PATIENTS | VIROLOGICAL SUPPRESSION | HIV-INFECTED PATIENTS
Journal Article
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, ISSN 0021-972X, 11/2012, Volume 97, Issue 11, pp. 4004 - 4013
Context: Vitamin D deficiency and insufficiency occur frequently in youth with HIV infection, particularly among those receiving the antiretroviral drug... 
CONTROLLED-TRIAL | CHOLECALCIFEROL | ABACAVIR-LAMIVUDINE | BONE-MINERAL DENSITY | ERGOCALCIFEROL VITAMIN-D-2 | D-DEFICIENCY RICKETS | ADOLESCENTS | ENDOCRINOLOGY & METABOLISM | ANTIRETROVIRAL THERAPY | D INSUFFICIENCY | TENOFOVIR
Journal Article
CLINICAL INFECTIOUS DISEASES, ISSN 1058-4838, 05/2018, Volume 66, Issue 9, pp. 1442 - 1447
Background. Human immunodeficiency virus (HIV)/hepatitis C virus (HCV)-coinfected individuals have a significantly greater osteoporotic fracture risk than... 
INFECTIOUS DISEASES | ABACAVIR-LAMIVUDINE | COINFECTION | MICROBIOLOGY | ANTIRETROVIRAL THERAPY |